No Data
No Data
Perspective Therapeutics Announces First Patient Treated With PSV359 In Phase 1/2A Dose-Finding Trial Assessing Safety And Preliminary Anti-Tumor Activity
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $17
Optimistic Buy Rating for Perspective Therapeutics Amid Strategic Clinical Developments and Strong Financial Position